{"id":473750,"date":"2021-04-08T14:54:14","date_gmt":"2021-04-08T18:54:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473750"},"modified":"2021-04-08T14:54:14","modified_gmt":"2021-04-08T18:54:14","slug":"scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/","title":{"rendered":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) <\/b><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fscott-scott.com%2Finvestigation%2Ffibrogen-inc%2F&amp;esheet=52408955&amp;newsitemid=20210408005887&amp;lan=en-US&amp;anchor=Scott%2BScott+Attorneys+at+Law+LLP&amp;index=1&amp;md5=75c6b04772bdd5c9bac3beae8dd621b6\">Scott+Scott Attorneys at Law LLP<\/a> (\u201cScott+Scott\u201d), an international shareholder and consumer rights litigation firm, is investigating whether FibroGen, Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) or certain of its officers and directors violated federal securities laws. If you purchased or otherwise own FibroGen stock, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312, or at <a rel=\"nofollow\" href=\"mailto:jzimmerman@scott-scott.com\">jzimmerman@scott-scott.com<\/a> for more information.\n<\/p>\n<p>\nIn November 2019, AstraZeneca and FibroGen presented results from a pooled safety analysis of six phase 3 trials purportedly showing that FibroGen\u2019s potential first-in-class anemia therapy, Roxadustat, was comparable to placebo on a composite of major cardiac events among non-dialysis patients, comparable to Epogen\/Procrit in dialysis-dependent patients, and superior to the erythropoietin drug in the incident dialysis subpopulation, which includes people new to dialysis.\n<\/p>\n<p>\nOn April 6, 2021, after the markets closed, FibroGen announced that this earlier data included \u201cpost-hoc changes to . . . stratification factors,\u201d which resulted in the drug appearing safer and\/or superior to Epogen-alfa in lowering the risk of cardiovascular events in certain kidney disease patients.\n<\/p>\n<p>\nOn this news, FibroGen\u2019s stock price fell sharply from $34.64 per share on April 6, 2021 to close at $19.74 on April 7, 2021, representing an over 43% decline in a single day.\n<\/p>\n<p><b>What You Can Do<\/b><\/p>\n<p>\nIf you purchased or otherwise own FibroGen stock, and you wish to discuss this investigation, please contact attorney Jonathan Zimmerman at (888) 398-9312, or at <a rel=\"nofollow\" href=\"mailto:jzimmerman@scott-scott.com\">jzimmerman@scott-scott.com<\/a>, or visit the FibroGen investigation page on our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fscott-scott.com%2Finvestigation%2Ffibrogen-inc%2F&amp;esheet=52408955&amp;newsitemid=20210408005887&amp;lan=en-US&amp;anchor=https%3A%2F%2Fscott-scott.com%2Finvestigation%2Ffibrogen-inc%2F&amp;index=2&amp;md5=1c70b71367dbbbc1b43abb6b0c791af4\">https:\/\/scott-scott.com\/investigation\/fibrogen-inc\/<\/a>.\n<\/p>\n<p><b>About Scott+Scott Attorneys at Law LLP<\/b><\/p>\n<p>\nScott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.\n<\/p>\n<p>\nAttorney Advertising\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210408005887\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210408005887\/en\/<\/a><\/span><\/p>\n<p><b>Jonathan Zimmerman<br \/>\n<\/b><br \/><b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fscott-scott.com%2Finvestigation%2Ffibrogen-inc%2F&amp;esheet=52408955&amp;newsitemid=20210408005887&amp;lan=en-US&amp;anchor=Scott%2BScott+Attorneys+at+Law+LLP&amp;index=3&amp;md5=240ce2c37260a684d4707c83fb3ff9e9\">Scott+Scott Attorneys at Law LLP<br \/>\n<\/a><\/b><br \/><b>230 Park Ave, 17<sup>th<\/sup> Fl, NY, NY 10169<br \/>\n<\/b><br \/><b>(888) 398-9312<br \/>\n<\/b><br \/><b><a rel=\"nofollow\" href=\"mailto:jzimmerman@scott-scott.com\">jzimmerman@scott-scott.com<\/a><\/b><\/p>\n<p><b>KEYWORDS:<\/b> United States North America New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210408005887\/en\/456736\/3\/Scott%2BScott_Logo_Large.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) NEW YORK&#8211;(BUSINESS WIRE)&#8211;Scott+Scott Attorneys at Law LLP (\u201cScott+Scott\u201d), an international shareholder and consumer rights litigation firm, is investigating whether FibroGen, Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) or certain of its officers and directors violated federal securities laws. If you purchased or otherwise own FibroGen stock, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312, or at jzimmerman@scott-scott.com for more information. In November 2019, AstraZeneca and FibroGen presented results from a pooled safety analysis of six phase 3 trials purportedly showing that FibroGen\u2019s potential first-in-class anemia therapy, Roxadustat, was comparable to placebo on a composite of major cardiac events among non-dialysis patients, comparable &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473750","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) NEW YORK&#8211;(BUSINESS WIRE)&#8211;Scott+Scott Attorneys at Law LLP (\u201cScott+Scott\u201d), an international shareholder and consumer rights litigation firm, is investigating whether FibroGen, Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) or certain of its officers and directors violated federal securities laws. If you purchased or otherwise own FibroGen stock, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312, or at jzimmerman@scott-scott.com for more information. In November 2019, AstraZeneca and FibroGen presented results from a pooled safety analysis of six phase 3 trials purportedly showing that FibroGen\u2019s potential first-in-class anemia therapy, Roxadustat, was comparable to placebo on a composite of major cardiac events among non-dialysis patients, comparable &hellip; Continue reading &quot;Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T18:54:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)\",\"datePublished\":\"2021-04-08T18:54:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/\"},\"wordCount\":369,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/\",\"name\":\"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-08T18:54:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/","og_locale":"en_US","og_type":"article","og_title":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Market Newsdesk","og_description":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) NEW YORK&#8211;(BUSINESS WIRE)&#8211;Scott+Scott Attorneys at Law LLP (\u201cScott+Scott\u201d), an international shareholder and consumer rights litigation firm, is investigating whether FibroGen, Inc. (\u201cFibroGen\u201d or the \u201cCompany\u201d) (NASDAQ: FGEN) or certain of its officers and directors violated federal securities laws. If you purchased or otherwise own FibroGen stock, and have suffered a loss, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312, or at jzimmerman@scott-scott.com for more information. In November 2019, AstraZeneca and FibroGen presented results from a pooled safety analysis of six phase 3 trials purportedly showing that FibroGen\u2019s potential first-in-class anemia therapy, Roxadustat, was comparable to placebo on a composite of major cardiac events among non-dialysis patients, comparable &hellip; Continue reading \"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T18:54:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)","datePublished":"2021-04-08T18:54:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/"},"wordCount":369,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/","name":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-08T18:54:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210408005887r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scottscott-attorneys-at-law-llp-announces-investigation-into-fibrogen-inc-fgen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Scott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473750"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473750\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}